Stay informed on developments in cancer and oncology diagnosis, prevention and treatment through these curated webinars. As the race toward a cure for cancer continues, advances in cancer research are constantly revealed as innovation in the field of oncology progresses.
Acute lymphoblastic leukemia is the most common cancer in children and adolescents. While current treatments have resulted in 85-90% cure, the remaining 10-15% cases represent the leading cau...
There are known health outcome disparities among those with pancreatic neuroendocrine tumors (pNET) of minority race and those living with adverse social determinants of health (SDOH) (rural...
Background: Healthcare access (HCA) encompasses five important dimensions: Affordability, Availability, Accessibility, Accommodation and Acceptability. Published studies of cancer typically...
The lack of diverse participation in clinical research and trials has been a long-standing national problem that has been brought to the forefront due to COVID 19. In cancer research less th...
Radiation therapy is an important cornerstone of oncologic therapy but is feared to the point of intimidation by too many patients. Yet by the end of treatment, most patients find the experi...
We recently determined that concurrent inhibition of autophagy, using the lysosomal inhibitor chloroquine (CQ), and of ERK, using a small molecule ERK inhibitor (ERKi), synergistically suppr...
Neoantigens are peptides derived from patient-specific and tumor-specific mutations, which can be recognized by the immune system and mediate tumor recognition that leads to immune destructi...
The future of cancer care is contingent on better understanding of molecular, clinical, and outcome data. This can be achieved by leveraging collaborative affiliations and networks locally a...
Over the past 10 years, we have come to a greater understanding of the pathogenesis of men who succumb to prostate cancer. One critical aspect is the role of molecular drivers in patients wi...
Discover how experience in utilizing a digital lab platform can elevate research workflows. Margriet will share insights, practical strategies, and success stories that demonstrate the benef...
Non-small cell lung cancer (NSCLC) accounts for more deaths than colon, breast, and prostate cancers combined. Of patients with NSCLC, 20% initially present with stage I or II disease, for w...
Data suggests that genetics comprises 42-58% of the prostate cancer risk. GWAS has found about 43% of the risk SNPs in Blacks and European Americans. Most of the SNPs that have been discover...
Technological advances in Artificial Intelligence (AI), particularly deep learning, have demonstrated remarkable progress in image-recognition tasks. Methods ranging from convolutional neura...
Key to precision oncology is the development of expert databases that organize and standardize information on cancer-related genetic variants, as well as their associated diagnostic, prognos...
Genomic research has long been skewed toward European populations, leading to significant underrepresentation of Non-European groups in both research studies and genomic databases. This bias...
Bromodomains (BRDs) are evolutionarily conserved protein domains that interact with acetylated histones and set off a chain of events that includes recruiting transcription factors and other...
Racial and ethnic minorities often experience cancer disparities in the United States with higher disease prevalence, shorter survival, and higher death rates with many cancer types. These d...
Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the defini...
In the United States, cancer disproportionately impacts Black and African American individuals. Identifying genetic factors underlying cancer disparities has been an important research focus...
One of the central tenants of biology is that our genetics—our genotype—influences the physical characteristics we manifest—our phenotype. But with more than 25,000 human g...
Uterine leiomyosarcoma (uLMS) is a rare aggressive sarcoma of the smooth muscle layer of the uterus manifested in high local recurrence and metastatic rate. Currently, effective treatment of...
There are currently several different FDA approved radiopharmaceuticals being used in both large academic and small practice settings to accurately stage and identify local and metastatic pr...
The microenvironment of many solid tumors impedes many immunotherapeutic treatments by inhibiting the effector functions of many classes of anti-tumor immune cells, including effector T cell...
Individuals with Lynch syndrome (LS) are prone to develop early-onset mismatch repair deficient (dMMR) colorectal- and endometrial cancers due to germline pathogenic variants (PVs) in one of...
Pancreatic ductal adenocarcinoma (PDAC) is characterized clinically by poor survival and mechanistically by KRAS- and autophagy-dependent growth. We and others previously demonstrated that i...
To determine efficacy of specific complementary therapies to advance evidence-based, integrative healthcare, the complementary modality should first be introduced to stakeholders to determin...
Jeff Borgia, Ph.D. is the Director of the Rush Cancer Center Biorepository, where he oversees the collection and annotation of patient specimens in support of ongoing translational research...
Acute lymphoblastic leukemia is the most common cancer in children and adolescents. While current treatments have resulted in 85-90% cure, the remaining 10-15% cases represent the leading cau...
